한글목차

세계 장시간 작용형 PEG-rhG-CSF 시장의 전망은 유망하며, 종양성 질환과 혈액 질환에 기회가 있습니다. 세계 장시간 작용형 PEG-rhG-CSF 시장은 2025년부터 2031년까지 CAGR 6.8%로 성장할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 암 유병률 증가, 지속형 생물학적 제제에 대한 선호도 증가, 바이오시밀러의 가용성 증가 등입니다.

• Lucintel의 예측에 따르면, 유형별로는 제네릭 의약품이 예측 기간 동안 높은 성장세를 보일 것으로 예상됩니다.
• 용도별로는 종양성 질환이 높은 성장세를 보일 것으로 예상됩니다.
• 지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장을 보일 것으로 예상됩니다.

장시간 작용형 PEG-rhG-CSF 시장의 새로운 동향

장시간 작용형 PEG-rhG-CSF 시장은 바이오의약품, 의료 경제, 암 치료의 환자 중심 치료 전략의 패러다임 변화를 반영하는 여러 가지 중요한 트렌드의 영향을 받고 있습니다.

• 바이오시밀러의 지배와 가격 침식 : 가장 강력한 추세는 페그필그라스팀의 바이오시밀러에 의한 시장 점유율 확대입니다. 더 많은 바이오시밀러가 시장에 진입하고 전 세계적으로 승인되면 가격 경쟁이 치열해져 의료 시스템에 상당한 비용 절감을 가져오고, 이 중요한 지지요법에 대한 환자 접근성을 확대할 수 있습니다.
• 환자 편의성과 자가투약의 중요성 : 페그필그라스팀은 환자의 편의성을 고려한 투약 시스템을 구축하여 사용하는 경향이 강해지고 있습니다. 안전성이 향상된 자동 주사기 시스템 및 프리필드 시린지는 점점 더 널리 보급되고 있으며, 환자에게 편의성을 제공하고, 병원 방문 빈도를 최소화하며, 특히 외래 환자 환경에서 치료 요법 순응도를 높일 수 있습니다.
• 가치와 비용효과성 입증의 중요성 : 의료비가 급증하는 상황에서 장시간 작용형 PEG-rhG-CSF의 비용효과성 및 가치를 입증하는 것은 특히 단시간 작용 G-CSF와 화학요법으로 인한 호중구감소증 및 관련 합병증(발열성 호중구감소증, 입원 등)의 치료비와의 관계에서 매우 중요합니다. 매우 중요합니다.
• 개별화된 투여 접근법 : 최근 증거에 따르면, 페그필그라스팀의 일률적인 투여량이 모든 사람에게 최선이 아닐 수 있다는 점이 강조되고 있습니다. 효율을 극대화하고 부작용을 최소화하기 위해 체중, 체표면적, 개별 화학요법 요법 등 환자별 파라미터를 이용한 개인별 맞춤 투여 접근법을 연구하는 움직임이 있습니다.
• 전체 암 치료 경로에 통합 : 장시간 작용하는 PEG-rhG-CSF는 화학요법 유발 호중구감소증에 대한 적절하고 시기적절한 예방을 제공하고 암 환자의 전반적인 관리 및 결과를 개선하기 위해 전체 암 치료 경로 및 치료 권장사항에 점점 더 많이 통합되고 있습니다. 통합되고 있습니다.

바이오시밀러 경쟁으로 인한 가격 인하, 새로운 전달 방식을 통한 환자 편의성 향상, 치료의 경제적 가치에 대한 강조, 보다 개인화된 치료 전략에 대한 고려, 일상적인 암 치료 관행에의 원활한 통합 등 이러한 추세는 장시간 작용형 PEG-rhG-CSF 시장에 변화를 불러일으키고 있습니다. 시장에 변화를 가져오고 있습니다.

장시간 작용형 PEG-rhG-CSF 시장의 최근 동향

장시간 작용형 PEG-rhG-CSF 시장은 지속적인 변화와 지지적 암 치료에 대한 영향력을 강조하는 중요한 신흥 시장의 발전으로 인해 많은 변화를 보이고 있습니다.

• 여러 바이오시밀러 제품의 상업화 및 개발 성공 : 주요 발전 중 하나는 페그필그라스팀의 바이오시밀러 제제가 여러 개 개발되어 규제 당국의 승인을 받아 주요 제약 시장에 출시되었다는 점입니다. 이는 오리지널 브랜드에 엄청난 경쟁을 가져왔고, 가격 인하의 주요 원동력이 되고 있습니다.
• 의료 전문가들의 지속적인 바이오시밀러 수용과 보급 : 페그필그라스팀 바이오시밀러는 기준 제제와 유사한 효능과 안전성 프로파일을 가지고 있어 의료 전문가들의 처방에 대한 익숙함과 안정감이 높아지고 있습니다. 바이오시밀러 제제의 시장 침투가 가속화되고 있습니다.
• 환자 편의성을 높이는 약물전달 기술 혁신 : 제약사들은 안전장치가 있는 프리필드 시린지, 자동주사펜 등 페그필그라스팀의 편리한 약물전달 기술 개발 및 도입에 주력해 왔습니다. 이러한 기술 혁신은 투여를 간소화하고 환자의 사용감을 향상시키는 것을 목표로 하고 있습니다.
• 바이오시밀러 사용을 뒷받침하는 실제 임상 증거 증가 : 일상 임상에서 페그필그라스팀 바이오시밀러의 유효성과 안전성을 입증하는 실제 임상시험(Real World Evidence)의 보고가 증가하면서 처방자와 환자들의 신뢰가 높아지고 있습니다.
• 연이은 특허 만료와 바이오시밀러의 신규 진입 : 주요 페그필그라스팀 제제의 특허 만료가 계속되면서 바이오시밀러의 신규 진입이 가능해져 시장 경쟁이 심화되고 가격이 하락할 가능성이 있습니다.

이러한 발전은 바이오시밀러를 통해 보다 저렴한 가격, 보다 쉬운 접근성, 첨단 전달 시스템을 통한 환자 투여 용이성, 바이오시밀러의 안전성과 효능에 대한 확고한 근거 기반, 시장 경쟁의 심화 등으로 인해 장시간 작용형 PEG-rhG-CSF 시장에 영향을 미치고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 거시경제 동향과 예측
• 업계 성장 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 장시간 작용형 PEG-rhG-CSF 시장 : 종류별

• 개요
• 매력 분석 : 종류별
• 혁신적 의약품 : 동향과 예측(2019-2031년)
• 제네릭 의약품 : 동향과 예측(2019-2031년)

제5장 세계의 장시간 작용형 PEG-rhG-CSF 시장 : 용도별

• 개요
• 매력 분석 : 용도별
• 종양성 질환 : 동향과 예측(2019-2031년)
• 혈액질환 : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 세계의 장시간 작용형 PEG-rhG-CSF 시장 : 지역별

제7장 북미의 장시간 작용형 PEG-rhG-CSF 시장

• 개요
• 북미의 장시간 작용형 PEG-rhG-CSF 시장 : 종류별
• 북미의 장시간 작용형 PEG-rhG-CSF 시장 : 용도별
• 미국의 장시간 작용형 PEG-rhG-CSF 시장
• 멕시코의 장시간 작용형 PEG-rhG-CSF 시장
• 캐나다의 장시간 작용형 PEG-rhG-CSF 시장

제8장 유럽의 장시간 작용형 PEG-rhG-CSF 시장

• 개요
• 유럽의 장시간 작용형 PEG-rhG-CSF 시장 : 종류별
• 유럽의 장시간 작용형 PEG-rhG-CSF 시장 : 용도별
• 독일의 장시간 작용형 PEG-rhG-CSF 시장
• 프랑스의 장시간 작용형 PEG-rhG-CSF 시장
• 스페인의 장시간 작용형 PEG-rhG-CSF 시장
• 이탈리아의 장시간 작용형 PEG-rhG-CSF 시장
• 영국의 장시간 작용형 PEG-rhG-CSF 시장

제9장 아시아태평양의 장시간 작용형 PEG-rhG-CSF 시장

• 개요
• 아시아태평양의 장시간 작용형 PEG-rhG-CSF 시장 : 종류별
• 아시아태평양의 장시간 작용형 PEG-rhG-CSF 시장 : 용도별
• 일본의 장시간 작용형 PEG-rhG-CSF 시장
• 인도의 장시간 작용형 PEG-rhG-CSF 시장
• 중국의 장시간 작용형 PEG-rhG-CSF 시장
• 한국의 장시간 작용형 PEG-rhG-CSF 시장
• 인도네시아의 장시간 작용형 PEG-rhG-CSF 시장

제10장 기타 지역(ROW)의 장시간 작용형 PEG-rhG-CSF 시장

• 개요
• 기타 지역(ROW)의 장시간 작용형 PEG-rhG-CSF 시장 : 종류별
• 기타 지역(ROW)의 장시간 작용형 PEG-rhG-CSF 시장 : 용도별
• 중동의 장시간 작용형 PEG-rhG-CSF 시장
• 남미의 장시간 작용형 PEG-rhG-CSF 시장
• 아프리카의 장시간 작용형 PEG-rhG-CSF 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업 간의 경쟁 관계
  • 구매자의 협상력
  • 공급업체의 협상력
  • 대체품의 위협
  • 신규 참여업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 성장 기회 : 종류별
  • 성장 기회 : 용도별
• 세계의 장시간 작용형 PEG-rhG-CSF 시장 최신 동향
• 전략 분석
  • 신제품 개발
  • 인증·라이선싱
  • 기업 인수합병(M&A) , 계약, 제휴, 합작투자

제13장 밸류체인 위 주요 기업 개요

• 경쟁 분석
• Amgen
• Pfizer
• Mylan
• Sandoz
• Biocon Biologics
• Coherus BioSciences
• Fresenius Kabi
• CSPC
• Qilu Pharmaceutical
• Jiangsu Hengrui Medicine

제14장 부록

• 그림목차
• 표목차
• 분석 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• Lucintel에 대해
• 문의

영문목차

The future of the global long-acting PEG-rhG-CSF market looks promising with opportunities in the neoplastic disease and blood disorder markets. The global long-acting PEG-rhG-CSF market is expected to grow with a CAGR of 6.8% from 2025 to 2031. The major drivers for this market are the rising prevalence of cancer, the growing preference for long-acting biologics, and the increasing availability of biosimilars.

• Lucintel forecasts that, within the type category, generic drugs are expected to witness higher growth over the forecast period.
• Within the application category, neoplastic disease is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Long-acting PEG-rhG-CSF Market

The Long-acting PEG-rhG-CSF market is under the impact of a number of important trends that mirror changing paradigms in biopharmaceuticals, healthcare economics, and patient-centered treatment strategies in oncology.

• Biosimilar Domination and Price Erosion: The strongest trend is the growing market share gain experienced by biosimilar versions of pegfilgrastim. With additional biosimilars entering the market and securing regulatory approval across the world, price competition will strengthen, causing substantial cost savings to healthcare systems and possibly expanding patient access to this critical supportive care drug.
• Focus on Patient Convenience and Self-Administration: There is an increasing trend towards the creation and use of patient-convenient administration systems for pegfilgrastim. Auto-injector systems and pre-filled syringes with improved safety features are becoming increasingly popular, providing patients with more convenience, minimizing the frequency of clinic visits, and potentially enhancing compliance with the treatment regimen, especially in the outpatient environment.
• Emphasis on Value and Cost-Effectiveness Demonstration: As costs of healthcare rise, there is great stress on proving the cost-effectiveness and value of Long-acting PEG-rhG-CSF, particularly in relation to shorter-acting G-CSFs and the expense of treating chemotherapy-induced neutropenia and related complications, e.g., febrile neutropenia and hospitalization.
• Personalized Dosing Approaches: Recent evidence is highlighting that one uniform dose of pegfilgrastim might not be the best for everyone. There is a move towards researching individualized dosing approaches by using patient-specific parameters such as body weight, body surface area, and individual chemotherapy regimens in an effort to maximize efficiency and minimize side effects.
• Integration into Overall Cancer Care Pathways: Long-acting PEG-rhG-CSF is being increasingly integrated into overall cancer care pathways and treatment recommendations so that appropriate and timely prophylaxis against chemotherapy-induced neutropenia is provided, leading to improved overall management of and outcomes in patients with cancer.

These trends are transforming the Long-acting PEG-rhG-CSF market by reducing prices through biosimilar competition, improving patient convenience with newer delivery approaches, highlighting the economic value of the therapy, looking at more individualized treatment strategies, and integrating it seamlessly into routine cancer care practices.

Recent Developments in the Long-acting PEG-rhG-CSF Market

The Long-acting PEG-rhG-CSF market has seen a number of critical developments that highlight its continued transformation and influence on supportive cancer care.

• Successful Commercialization and Development of Several Biosimilar Products: One of the major developments is that several biosimilar versions of pegfilgrastim have been successfully developed, approved by the regulatory authorities, and launched across key pharma markets. This has brought immense competition to the originator brand and has been a primary driver of price cuts.
• Sustained Acceptance and Uptake of Biosimilars by Healthcare Professionals: With time, healthcare professionals have grown more accustomed and comfortable prescribing pegfilgrastim biosimilars, aware of their similar efficacy and safety profiles with the reference product. Sustained acceptance has promoted enhanced market penetration of biosimilars.
• Innovation in Drug Delivery Technologies for Patient Convenience: Pharmaceutical companies have focused on developing and implementing user-friendly drug delivery technologies for pegfilgrastim, such as pre-filled syringes with safety mechanisms and auto-injector pens. These innovations aim to simplify administration and improve the patient experience.
• Increasing Body of Real-World Evidence in Support of Use of Biosimilars: More real-world evidence studies are being reported documenting the efficacy and safety of pegfilgrastim biosimilars in everyday clinical practice, continuing to build prescriber and patient confidence.
• Repeated Expiration of Patents and New Biosimilar Players: Continued expiration of patents on important pegfilgrastim products continues to open the doors for new biosimilar players to come into the market, adding more competition and possibly pushing prices lower.

These advances are affecting the Long-acting PEG-rhG-CSF market by making it more affordable and accessible using biosimilars, making administration easier for patients with advanced delivery systems, establishing a robust evidence base for biosimilar safety and efficacy, and creating a more competitive market setting.

Strategic Growth Opportunities in the Long-acting PEG-rhG-CSF Market

The Long-acting PEG-rhG-CSF market, although mainly developed for the prevention of chemotherapy-induced neutropenia, has a number of strategic growth opportunities across key applications in oncology and hematology.

• Increasing Prophylactic Application in Moderate-Risk Chemotherapy Regimens: Pegfilgrastim is usually recommended by current guidelines for high-risk regimens. An emerging opportunity exists with the identification and expansion of its prophylactic application in certain moderate-risk regimens where the cost may be offset by the benefit of avoiding neutropenic complications, especially given the availability of biosimilars at lower costs.
• Tapering Dosing Strategies in Special Patient Populations: Studies on patient-specific dosing based on various factors like body weight, age, and comorbidities can result in more effective and cost-conscious utilization of pegfilgrastim among such patient groups, offering a future growth opportunity through resource optimization.
• Investigating Use with Next-Generation Cancer Therapies: With each new myelosuppressive cancer therapy introduced, such as targeted therapies and immunotherapies, integrated into treatment combinations, there might be an escalating demand for prophylactic pegfilgrastim to alleviate related neutropenia, constituting a strategic growth opportunity.
• Growing Adoption in Emerging Economies with Value Biosimilars: Availability of lower-priced biosimilar equivalents of pegfilgrastim presents a big growth opportunity to increase access to this critical supportive care in emerging economies where price can be an important obstacle to treatment. Distribution networks and partnership strategies will play a key role.
• Examining Use in Hematopoietic Stem Cell Transplant: Although mostly utilized in chemotherapy-induced neutropenia, the potential use of pegfilgrastim in hematopoietic stem cell mobilization can be studied further and optimized and may widen its use in transplantation.

Profiting from such strategic expansion opportunities demands constant clinical research to streamline treatment protocols and determine new uses, manufacturing specific dosing strategies and preparations, as well as successful market access tactics, especially for biosimilars in underdeveloped areas.

Long-acting PEG-rhG-CSF Market Driver and Challenges

The Long-acting PEG-rhG-CSF market is affected by an intricate interrelationship of drivers and challenges emanating from clinical demand, technological development, economic pressures, and regulatory frameworks controlling biopharmaceuticals.

The factors responsible for driving the long-acting PEG-rhG-CSF market include:

1. Established efficacy in prevention of chemotherapy-induced neutropenia: The strong clinical evidence that proves the efficacy of pegfilgrastim in the prevention of the incidence and severity of neutropenia continues to be the major reason for its application in patients undergoing myelosuppressive chemotherapy.

2. Growing global prevalence of cancer and chemotherapy use: The increasing global cancer burden and the persistent use of chemotherapy as an important treatment strategy guarantee an ongoing demand for supportive treatments such as pegfilgrastim.

3. Increasing availability and acceptance of biosimilars: Increased numbers of approved and commercially available pegfilgrastim biosimilars offer lower-cost treatment alternatives, increasing market access and overall market volume.

4. Convenience and friendly patient delivery device development: The availability and usage of auto-injectors increase patient convenience and compliance, further enhancing pegfilgrastim usage, especially among outpatients.

5. Reimbursement policy and supportive clinical practice guidelines: Favorable reimbursement policies in most healthcare systems and recommendations of oncology organizations allow the utilization of pegfilgrastim in suitable clinical practice settings.

Challenges in the long-acting PEG-rhG-CSF market are:

1. Increasing price competition from biosimilars: The rise in the number of biosimilar entrants creates huge price erosion, affecting the profitability and revenues of both biosimilar and originator manufacturers.

2. Optimal patient selection and personalized dosing: Who to treat and how much pegfilgrastim to give them remain subjects for ongoing investigation and optimization.

3. Coping with the cost burden on healthcare systems: Even in the presence of biosimilars, overall supportive cancer care costs, including pegfilgrastim, continue to pose a challenge for healthcare payers and systems around the world.

In summary, the Long-acting PEG-rhG-CSF market is fueled by its proven efficacy, the mounting demand for neutropenia treatment because of the rising burden of cancer globally, the availability of cheaper biosimilars, and improved delivery device advancements. Nevertheless, the market is challenged by heightening price competition, the demand for individually customized treatment strategies, and the sheer cost burden on healthcare systems.

List of Long-acting PEG-rhG-CSF Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leveraging integration opportunities across the value chain. With these strategies, long-acting PEG-rhG-CSF companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the long-acting PEG-rhG-CSF companies profiled in this report include:

• Amgen
• Pfizer
• Mylan
• Sandoz
• Biocon Biologics
• Coherus BioSciences
• Fresenius Kabi
• CSPC
• Qilu Pharmaceutical
• Jiangsu Hengrui Medicine

Long-acting PEG-rhG-CSF Market by Segment

The study includes a forecast for the global long-acting PEG-rhG-CSF market by type, application, and region.

Long-acting PEG-rhG-CSF Market by Type [Value from 2019 to 2031]:

• Innovative Drugs
• Generic Drugs

Long-acting PEG-rhG-CSF Market by Application [Value from 2019 to 2031]:

• Neoplastic Diseases
• Blood Disorders
• Others

Long-acting PEG-rhG-CSF Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Long-acting PEG-rhG-CSF Market

The Long-acting PEG-rhG-CSF market, a cornerstone of supportive cancer care, continues to evolve with a strong emphasis on biosimilar competition and enhanced patient convenience. Designed to reduce the incidence of chemotherapy-induced neutropenia with less frequent dosing than short-acting G-CSFs, pegfilgrastim has become a standard of care. Recent developments are characterized by the increasing availability and uptake of biosimilar versions, driving price adjustments and expanding patient access globally. Delivery device innovations, including pre-filled syringes and auto-injectors, are also significantly contributing to defining market trends in various regions.

• United States: Significant biosimilar erosion has occurred within the US Long-acting PEG-rhG-CSF market, driving considerable cost savings for patients and healthcare providers alike. Recent changes have involved the ongoing introduction of new biosimilars, as well as fierce price wars between manufacturers. The emphasis lies in balancing affordability with maintaining a consistent level of access to this critical supportive treatment for patients on myelosuppressive chemotherapy.
• China: China's market for Long-acting PEG-rhG-CSF is experiencing swift growth, fueled by an expanding cancer patient base and rising uptake of sophisticated cancer therapies. Developments in the recent past include the approval and launch of multiple locally manufactured pegfilgrastim biosimilars. The biosimilars are reducing the cost of therapy and making it more accessible, driving strong market growth and greater competition with the reference product.
• Germany: The German healthcare system has easily adopted biosimilar forms of Long-acting PEG-rhG-CSF, leading to significant cost savings. Recent advancements include a high level of biosimilar prescribing, fueled by positive reimbursement policies and physician acceptance. The market focuses on guaranteeing the quality and effectiveness of biosimilars while maximizing healthcare spending for supportive cancer care.
• India: Long-acting PEG-rhG-CSF in India is marked by rising affordability and accessibility, which is mainly attributed to the availability of a number of local biosimilar producers. Recent trends encompass greater usage of these economic alternatives in both public and private sectors. Measures are being taken to implement strict quality control and increase access across the nation.
• Japan: Japan's market for Long-acting PEG-rhG-CSF is witnessing a slow but consistent rise in the adoption of biosimilars. Recent events include cautious assessment of the safety and performance of biosimilar products by regulators and healthcare professionals. Although the rate of adoption is relatively conservative, cost-containment pressures are likely to propel more biosimilar penetration in the next few years.

Features of the Global Long-acting PEG-rhG-CSF Market

• Market Size Estimates: Long-acting PEG-rhG-CSF market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Long-acting PEG-rhG-CSF market size by type, application, and region in terms of value ($B).
• Regional Analysis: Long-acting PEG-rhG-CSF market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the long-acting PEG-rhG-CSF market.
• Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the long-acting PEG-rhG-CSF market.

Analysis of the competitive intensity of the industry based on Porter's Five Forces model.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the long-acting PEG-rhG-CSF market by type (innovative drugs and generic drugs), application (neoplastic diseases, blood disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Long-acting PEG-rhG-CSF Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Innovative Drugs: Trends and Forecast (2019-2031)
• 4.4 Generic Drugs: Trends and Forecast (2019-2031)

5. Global Long-acting PEG-rhG-CSF Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Neoplastic Diseases: Trends and Forecast (2019-2031)
• 5.4 Blood Disorders: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Long-acting PEG-rhG-CSF Market by Region

7. North American Long-acting PEG-rhG-CSF Market

• 7.1 Overview
• 7.2 North American Long-acting PEG-rhG-CSF Market by Type
• 7.3 North American Long-acting PEG-rhG-CSF Market by Application
• 7.4 United States Long-acting PEG-rhG-CSF Market
• 7.5 Mexican Long-acting PEG-rhG-CSF Market
• 7.6 Canadian Long-acting PEG-rhG-CSF Market

8. European Long-acting PEG-rhG-CSF Market

• 8.1 Overview
• 8.2 European Long-acting PEG-rhG-CSF Market by Type
• 8.3 European Long-acting PEG-rhG-CSF Market by Application
• 8.4 German Long-acting PEG-rhG-CSF Market
• 8.5 French Long-acting PEG-rhG-CSF Market
• 8.6 Spanish Long-acting PEG-rhG-CSF Market
• 8.7 Italian Long-acting PEG-rhG-CSF Market
• 8.8 United Kingdom Long-acting PEG-rhG-CSF Market

9. APAC Long-acting PEG-rhG-CSF Market

• 9.1 Overview
• 9.2 APAC Long-acting PEG-rhG-CSF Market by Type
• 9.3 APAC Long-acting PEG-rhG-CSF Market by Application
• 9.4 Japanese Long-acting PEG-rhG-CSF Market
• 9.5 Indian Long-acting PEG-rhG-CSF Market
• 9.6 Chinese Long-acting PEG-rhG-CSF Market
• 9.7 South Korean Long-acting PEG-rhG-CSF Market
• 9.8 Indonesian Long-acting PEG-rhG-CSF Market

10. ROW Long-acting PEG-rhG-CSF Market

• 10.1 Overview
• 10.2 ROW Long-acting PEG-rhG-CSF Market by Type
• 10.3 ROW Long-acting PEG-rhG-CSF Market by Application
• 10.4 Middle Eastern Long-acting PEG-rhG-CSF Market
• 10.5 South American Long-acting PEG-rhG-CSF Market
• 10.6 African Long-acting PEG-rhG-CSF Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Long-acting PEG-rhG-CSF Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Amgen
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Pfizer
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Mylan
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Sandoz
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Biocon Biologics
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Coherus BioSciences
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Fresenius Kabi
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 CSPC
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Qilu Pharmaceutical
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Jiangsu Hengrui Medicine
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us